• AI-driven approaches and high-throughput screening have significantly accelerated the drug discovery process, reducing time and cost.
• PROTACs and CRISPR-based gene editing represent transformative modalities for targeting previously undruggable proteins and correcting genetic defects.
• Overcoming drug resistance and ensuring safety remain critical hurdles, necessitating innovative trial designs and biomarkers.
• Personalized medicine, guided by genomic and proteomic profiling, is poised to reshape therapeutic paradigms, improving efficacy and minimizing adverse effects.